Discovering Patterns in Experiences of Patients in Esophageal Cancer Clinical Research

NCT05831150 | Not Yet Recruiting

• 1 other identifier: 82828643
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

Participation in clinical trials usually favors a particular demographic group. But there is limited research available to explain what study attributes affect the completion of these specific demographic groups. This study will investigate the safety and efficacy of esophageal cancer treatments. The focus will be on tracking the rates of completion and withdrawal among these individuals. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future esophageal cancer research.

Conditions

Esophageal Cancer

Keywords

esophageal cancer

Outcome Measures

Primary Outcomes (2)

• Rate of patients who decide to enroll in a clinical research.

  3 months

• Number of study participants who remain in clinical research until completion.

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients who are actively considering involvement in an observational esophageal cancer clinical trial, but have not yet completed enrollment and registration.

You may qualify if:

• Patient is at least 18 years of age
• Diagnosis of esophageal cancer
• Ability to understand a written informed consent document, and the willingness to sign it.

You may not qualify if:

• Women of childbearing potential without a negative pregnancy test; or women who are lactating.
• Has a serious medical or psychiatric illness likely to interfere with participation in this clinical study.
• Inability to perform regular electronic reporting

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Related Publications (3)

• Kim HJ, Bains MS. Randomized clinical trials in esophageal cancer. Surg Oncol Clin N Am. 2002 Jan;11(1):89-109, viii. doi: 10.1016/s1055-3207(03)00076-0.

  PMID: 11928803 BACKGROUND

• Harada K, Rogers JE, Iwatsuki M, Yamashita K, Baba H, Ajani JA. Recent advances in treating oesophageal cancer. F1000Res. 2020 Oct 1;9:F1000 Faculty Rev-1189. doi: 10.12688/f1000research.22926.1. eCollection 2020.

  PMID: 33042518 BACKGROUND

• Zhou N, Hofstetter WL. Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer. Expert Rev Mol Diagn. 2020 Apr;20(4):401-411. doi: 10.1080/14737159.2020.1731307. Epub 2020 Feb 24.

  PMID: 32067548 BACKGROUND

MeSH Terms

Conditions

Esophageal Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

415-900-4227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 14, 2023
• First Posted: April 26, 2023
• Study Start: May 1, 2024
• Primary Completion: May 1, 2025
• Study Completion: May 1, 2026
• Last Updated: April 26, 2023

Record last verified: 2023-04